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Xintian Huang, MD, Min Lu, MD, and Mi’er Jiang, MD, Shanghai, China
Background: Venous malformations (VMs) are the commonest vascular anomalies. Treatment of extratruncular venous
malformations (EVMs) is difficult. Surgery has been the mainstay therapy for EVMs but can be hazardous, leading to
major blood loss and incomplete resection. Recurrence and cosmetic problems are also common after resection.
Endovenous laser ablation (EVLA) has been found to be safe and effective for endovenous ablation of incompetent
saphenous veins. We report our experience of diode laser ablation in percutaneous ultrasound (US)-guided treatment of
congenital EVMs with respect to effectiveness and safety.
Methods:A consecutive series of patients (16 males and 22 females; age, 13-46 years) were treated by US-guided EVLA for
EVMs at our institution. A questionnaire was used to assess preoperative and postoperative symptoms. Effectiveness was
assessed by procedural success and clinical success. Subjective improvement of symptoms was further assessed simulta-
neously with objective evidence of improved clinical signs. This included reduction of lesion size, general swelling, or
improved range of motion of the joint. Duplex US imaging was used to assess blood flow within lesions. Safety was
assessed by morbidity and mortality, including laser-related adverse events, postoperative deep vein thrombosis,
pulmonary embolism, and hematoma.
Results: All patients tolerated the procedure and recovered uneventfully. Fifty-six procedures were undertaken in 38
patients. All procedures were successful. Thirty-three patients had resolution of presenting pain symptoms after laser
treatment; the remaining patients were able to significantly reduce the number of pain medications from that used before
treatment. For complaints related to swelling and cosmetic effect, clinical success was 70% and 67%, respectively. No
patients returned with recurrent symptoms after initial successful treatment at a mean follow-up of 12.7 months.
Thirty-six (64%) treated lesions areas were classified as “excellent,” 18 (32%) were “good,” and 2 (4%) were “fair” using
duplex US imaging at final follow-up. Better results were obtained with localized types of VMs, in which palliation was
achieved after only one treatment. Complications were minor and improved quickly.
Conclusions: Treatment of congenital EVMs with endovenous laser ablation under US guidance achieved palliation in
most symptomatic patients; it was safe, with minimal morbidity during short-term follow-up. ( J Vasc Surg 2011;
54:139-45.)
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dVenous malformations (VMs) are congenital, comprise
two-thirds of vascular malformations, and are formed from
venules and large veins. The Hamburg Classification Sys-
tem appropriately classifies congenital vascular malforma-
tions using criteria that take into account the underlying
anatomic, histologic, pathophysiologic, and hemodynamic
status of these defects that are derived from different em-
bryonic stages. After a VM lesion is diagnosed, the VM
subtype is further identified as extratruncular VM (EVM)
or truncular.1,2 The truncular subtype has lost the embry-
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doi:10.1016/j.jvs.2010.11.105nic characteristics of the mesenchymal cells along with the
otential to grow and proliferate, resulting in minimal risk
f recurrence.3,4 The EVM subtype is a histologically be-
ign lesion that typically grows in size with the patient and
ay undergo accelerated growth during adolescence, preg-
ancy, surgery, or trauma.3,4 It may occur as a localized or
iffusely infiltrating lesion. They usually consist of collec-
ions of abnormal interconnecting channels or spaces that
re “sequestered” or drain through fairly small vessels to
ormal adjacent conducting veins, and interconnected
hannels penetrate normal tissues.3,4
VMs can present with a variable clinical manifestation.
hey can cause pain, a reduced range of movement, com-
ression of adjacent structures, bleeding, consumptive co-
gulopathy, and cosmetic deformity.4 Treatment of VMs is
ifficult. Surgery has been the classic therapy for VMs, but
esection may be hazardous, leading to major loss of blood
nd incomplete resection. Recurrence and cosmetic prob-
ems are also common after resection.5,6
Procedures that are much less invasive have emerged as
ffective and frequently durable alternatives in the last two
ecades, but they have limitations. Endovascular treatment
ith sclerotherapy is now well accepted as “independent
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July 2011140 Lu et altherapy” for surgically inaccessible lesions and for patients
with diffuse, infiltrating EVMs who are unfit for surgery.6,7
Ethanol sclerotherapy is also the treatment of choice for
extensive lesions that extend beyond the deep fascia with
involvement of muscle, tendon, and bone. However, per-
cutaneous ethanol sclerotherapy can result in skin necrosis,
nerve damage, and rarely, cardiopulmonary arrest.8,9
The diode laser is a recently developed energy source
that has been found to be safe and effective for endovenous
ablation of the incompetent saphenous vein in adults. En-
doluminal laser therapy is a minimally invasive therapy that
may offer less systemic and local morbidity than chemical
sclerotherapy.10,11 We report our experience with diode
laser ablation in percutaneous ultrasound (US)-guided
treatment of congenital EVMs with respect to the proce-
dure, outcome, and complications.
PATIENTS AND METHODS
We obtained approval from the local Institutional Re-
view Board to conduct the present study.
Patient selection. We retrospectively reviewed the re-
cords of all patients who started US-guided endovenous
treatment of EVMs using an 810-nm diode laser at our
institution between May 2007 and May 2009.
Physical examination of patients with VMs includes a
general inspection of the affected area. The following fea-
tures are noted: skin involvement, thrombi, tenderness,
range of movement, skin temperature, peripheral pulses,
and changes in the size of the lesion with dependency and
elevation. Typically, EVMs are soft and compressible; they
become much smaller if the affected area is elevated and
distended with dependency.
All patients underwent a preprocedural magnetic reso-
nance imaging (MRI) and duplex US study to investigate
the depth of the malformation and tissue involvement.
Patients with VMs due to glomuvenous malformations,
and various syndromes (Maffucci; Klippel-renaunay; Bean)
were not included in the series.
The main criterion for study inclusion was a diagnosis
of EVMs according to TheHamburg Classification System.
Also, patients who were indicated for endovenous laser
treatmentmet at least one of the following criteria: they had
lesions with symptoms and signs (eg, pain, discomfort,
“heavy” sensation, difficulty in moving about and moving
joints, swelling, limited range of motion, hemorrhage),
with significant functional impairment or cosmetically se-
vere deformity, located at trauma-prone regions (knee,
ankle, foot, elbow, wrist, hand) with an increased risk of
complications (eg, hemarthrosis).
Lesions were categorized using MRI on the basis of
lesion margins. EVMs were divided into two categories:
● EVMs with a well-defined or circumscribed margin
with a sharp abrupt transition from the surrounding
tissue that remained confined to its tissue and fascial
plane were defined as limited VMs.
● EVMs with an ill-defined margin with an irregular
interface with the surrounding tissue that appeared to vcross tissue and fascial planes were defined as infiltrat-
ing VMs.7,8
Hematologic evaluation, including a complete blood
ount, clotting parameters, fibrinogen, and D-dimers was
one for patients, except for those with small lesions.
reatment was delayed if the hematologic evaluation re-
ealed a significant decrease in fibrinogen. Each symptom
nd sign that the patient had before treatment was metic-
lously documented by the patient or family members
hrough appropriate description, including photographs.
Procedure. EVMs on limb extremities were treated
ith laser ablation using epidural or lumbar anesthesia; if
hey were on the neck, chest, and back, general anesthesia
as used. Before being sedated, patients were asked to
oint out the most subjectively bothersome portion of the
esion. An 810-nm diode laser (Diomed, Limited, Cam-
ridge, UK) was used to generate sufficient heat to cause
hermal damage to the venous endothelium. The laser
omprises a continuous-wave 810-nm diode laser source
nd a disposable 600-m bare-tipped fiber.
We treated only portions of the lesions visible by US
maging; we did not attempt to treat deeper portions of the
esions not visible by US imaging. For small lesions, we
ttempted to treat the entire lesion at each setting.12 In
arger lesions, only a portion was treated at each session;
his was chosen by the patient or was selected due to visible
welling.
After a sterile field was obtained, percutaneous access
as established with US guidance with a 3F vascular sheath
sing the Seldinger approach or directly with an 18-gauge
ntravenous catheter. At each of these sites, an 18-gauge
ntravenous catheter or a 3F vascular sheath was inserted to
he level of the malformation with US guidance (Fig 1, a).
backflow of blood confirmed accurate placement of the
atheter. A 600-m optical fiber was then threaded
hrough the catheter. The sheath or catheter was retracted
o expose the distal 2 to 3 cm of the laser fiber. The laser
ystem was calibrated to deliver pulses at a wavelength of
10 nm with 10 to 13W of energy (chosen by the operator
t the time of the procedure according to the size of the
hannels) and a pulse duration of 1 second on each trigger
sing a foot pedal. In this series, US guidance was used not
nly for positioning of the laser within the venous channels
ut also to monitor the formation and distribution of
icrobubbles in real time. The aim of selecting the appro-
riate level of power was to treat the selected venous
hannels (which vary in size) and to reduce the risk of
ontarget thrombosis.
The fiber was slowly withdrawn toward the skin surface
s microbubbles were seen to fill the channels (Fig 1, b). If
he microbubbles were not seen to contact vein walls, the
aser energy was increased (ie, the number of pulses was
ncreased). If bubbles were seen to travel toward known
utflow veins, treatment was concluded in that channel to
educe the risk of systemic embolization. If the laser fiber
as sufficiently superficial so that the red aiming beam was
isible through the skin, the skin was observed directly to
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Volume 54, Number 1 Lu et al 141look for a change in skin color as an indicator of early skin
burns. Placement of the surgeon’s hand over the treatment
area avoided overheating of the skin.
On complete removal of the fiber, manual pressure was
applied to the treated areas for several minutes. Multiple
punctures were then applied. Puncture points were placed
around the circumference of the lesion nidus under US
guidance. The catheter position within the lesion nidus was
confirmed by aspiration of nonpulsatile venous blood. A
Fig 1. a, Sheath was inserted to the level of the malformation
with duplex ultrasound guidance. b, Microbubbles filled the le-
sions.600-m optical fiber was then threaded through the cath- tter for laser treatment. The catheter position within the
esion nidus with US guidance but without a backflow of
lood signaled an end point of treatment. The total energy
elivered was calculated as a product of the power (in
atts), pulse duration (in seconds), and the total number of
ulses. This value was recorded in the surgical notes.
On the completion of treatment, external pressure
as applied to the treated areas with elastic bandages for
days. For EVMs on limb extremities, a class III (30-40
m Hg) full-thigh graduated support stocking or panty
ose was worn for at least 1 month at all times (except
hen sleeping or showering) during follow-up. Patients
ere admitted for 1 to 3 days for observation. They were
ischarged with instructions to take acetaminophen or
buprofen (if needed) and to call or return to the hospital
f they had severe local pain, numbness, chest pain,
yspnea, or skin changes. Patients returned for follow-up
weeks after endovenous laser treatment. Physical ex-
mination of the treated area, bidirectional Doppler, and
uplex US examinations were done to check for blood
ow in the treated lesion. Similar evaluations were done
t each follow-up visit. Clinical and duplex US follow-up
as done at 2 weeks and at 3, 6, and 12 months, and then
nnually.
Study end points and definitions. Procedural suc-
ess was defined as filling of the treated area with micro-
ubbles and multiple punctures around the circumference
f the lesion nidus under US guidance without a backflow
f blood. Clinical success was defined as resolution or
arked improvement of presenting symptoms according to
he patient. This subjective improvement of symptoms was
urther assessed simultaneously with objective evidence of
mproved clinical signs, including reduction of the size
f lesion, general swelling, or improved range of motion of
he joint. Minor complications were defined as those re-
uiring no therapy or nominal therapy with no conse-
uences. Major complications were defined as those requir-
ng therapy, an increased level of care, or permanent
dverse sequelae. Imaging studies were analyzed by con-
ensus by one radiologist and one surgeon; for example,
uplex US can assess blood flow within a lesion.
Complete cessation of flow at the treated nidus was
efined as “excellent” (Fig 2). Near-complete cessation,
ut with some suspicion along the feeding artery and
raining veins, was defined as “good.” Drastic reduction,
ut with substantial evidence of residual activity of the
reated nidus was defined as “fair.” Periodic follow-up
valuations of treatment results were made every 6 months
y the multidisciplinary team.
ESULTS
Patient characteristics. Thirty-eight patients (16
ales and 22 females) who were a mean age of 35.6 years
range, 13-46 years) with extratruncular limited (n 6) or
nfiltrating (n  32) VMs according to the Hamburg
lassification System underwent US-guided diode laser
reatment over a 48-month period. Lesions were located on
he shoulder (n 4), chest (n 3), back (n 3), forearm
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July 2011142 Lu et al(n 11), and lower extremity (n 17). The diagnosis was
made with typical clinical parameters and imaging findings
(Table I). Eight patients had undergone at least one previ-
ous attempt to remove the lesion by surgical means. Three
of these eight patients had a lesion on the upper extremity
and five patients had a lesion on a lower extremity. These
patients were looking for a different treatment when their
symptoms recurred a few months after excisional surgery.
One patient had also been treated by percutaneous sclero-
therapy with Sotradecol, but only transient improvement
was obtained. In 21 of the 38 patients, phleboliths were
Fig 2. Duplex ultrasound appearance of the lesions (
follow-up.seen on plain radiographs before treatment. pAll patients with a lesion on an extremity were treated
rst with a tailored compression garment, but symptoms
ontinued despite this treatment. Of the 38 patients, 21
ad one endovascular laser treatment (7 lower extremities,
upper extremities, 3 chests, 2 shoulders, and 2 backs), 16
ad two sessions (10 lower extremities, 4 upper extremities,
shoulders, 1 back, and 1 chest), and 1 patient had three
essions of endovascular laser treatment (lower extremity).
ll extratruncular limited VMs had one endovascular laser
reatment. For infiltrating VMs, we treated only portions of
he lesions that displayed symptoms and did not treat other
before treatment and (c, d) after treatment duringa, b)arts of the lesions. Two or three sessions were done for
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Volume 54, Number 1 Lu et al 143portions of infiltrating VMs (residual lesions) that were not
treated.
Therapeutic effects. Thirty-eight patients underwent
56 procedures, and all were technically successful. The
mean interval between sessions was 4.3 months. The laser
catheter was inserted a mean of 13 times at each treatment
session. All patients tolerated the procedure well and recov-
ered uneventfully.
Follow-up time was calculated from the time laser
procedure was done, and was a mean of 12.7 months
(range, 2-24 months). After laser treatment, presenting
pain symptoms resolved in 33 patients, and the remaining
patient was able to significantly reduce the number of pain
medications from that used before treatment; therefore,
the clinical success for treating pain symptoms was 100%.
No patients have returned with recurrent symptoms after
initial successful treatment at a mean follow-up of 12.7
months.
Better results were obtained with the localized type; in
most of these, palliation was achieved after only one treat-
ment. Patients with diffuse lesions required repeat sessions
in untreated areas with relief of symptoms. Most lesions
decreased in size after laser treatment according to patient
reports. We noticed that many of the lesions seemed to be
flatter and less distensible according to patient report and
physical examination; therefore, for complaints related to
swelling and cosmetic effect, the clinical success was 70%
and 67% (Table II).
Although laser use in proximity to brachial plexus was
avoided, the five patients with pretreatment activity limita-
tion could resume all activities after treatment. Duplex US
assessment of the treated lesions at the final follow-up
showed 36 (64%; 5 limited VMs and 31 infiltrating VMs)
were “excellent,” 18 (32%; 1 limited VM, 17 infiltrating
VMs) were “good,” and 2 (4%; 2 infiltrating VMs) were
Table I. Patient characteristics
EVM
Limited Infiltrating Total
Sex, No.
Males 3 13 16
Females 3 19 22
Age, years (mean) 32.5 27.8 28.5
Lesion location, No.
Shoulder 2 2 4
Chest 1 2 3
Back 0 3 3
Forearm 2 9 11
Lower extremity 1 16 17
Symptoms and signs, No.
Pain 5 46 51
Heavy sensation 0 17 17
Limited range of motion 1 6 7
Hemorrhage 0 5 5
Swelling 5 42 47
Deformity 2 19 21
EVM, Extratruncular venous malformation.“fair.” oComplications. Pain and indurations are common ad-
erse events associated with diode laser treatment of EVMs
ut are self-limiting in most cases. Only five patients re-
uired treatment with over-the-counter analgesics (ibupro-
en) for 1 to 2 weeks. For superficial lesions, ecchymosis or
iscoloration beneath the skin along the course of treated
reas is common, but this symptom usually abates in 2 to 4
eeks. Spot skin burn injuries occurred in one patient and
esolved in 4 weeks. Paresthesia in the treated area was
oted in 13 limbs (5.48%) but disappeared in 1 to 3
onths. A decrease in the level of fibrinogen after laser
reatment was found in six patients, but recovered in 2 to 4
eeks. No hemorrhage occurred. No other potential com-
lications such as deep vein thrombosis, pulmonary embo-
ism, or hematoma developed, and all of the minor compli-
ations resolved without sequelae.
ISCUSSION
The extratruncular form of VM lesions arises if devel-
able II. Therapeutic effects
EVMs
ariable Limited Infiltrating Total
ean diameter, cm 5.6 12.3 11.24
umber of sessions 1 (21) 1 (17) 56c
2 (16)
3 (1)a
umber of passes 11.5 13.3 13
ollow-up, months 13.2 12.6 12.7
ymptoms and signs
Pain 5 46 51
Resolved 5 28 33
Markedly improved 0 18 18
Heavy sensation 0 17 17
Resolved 0 11 11
Markedly improved 0 3 3
Limited range of
motion
1 6 7
Resolved 1 2 3
Markedly improved 0 4 4
Hemorrhage 0 5 5
Resolved 0 5 5
Markedly improved 0 0 0
welling 5 42 47
Resolved 4 9 13
Markedly improved 1 19 20
Deformityb 2 19 21
Resolved 2 3 5
Markedly improved 0 9 9
US assessment‡
Excellent 5 31 36
Good 1 17 18
Fair 0 2 2
VMs, Extratruncular venous malformations; US, ultrasound.
Twenty-one of the 38 patients had one endovascular laser treatment, 16
atients had two treatments, and one patient had three treatments.
Deformity: Morphologic changes of local sessions.
Fifty-six procedures were undertaken in 38 patients. Patients with diffuse
esions had repeat sessions outside the treated areas for relief of symptoms.
uplex US was used to assess blood flow in all treated lesions.pmental arrest occurs in the early stage of embryonic life
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July 2011144 Lu et alwhile the vascular system is in the reticular stage. They are
embryonic tissue remnants of mesodermal origin that re-
tain the characteristics of mesenchymal cells and their po-
tential to grow and proliferate if stimulated internally (eg,
menarche, pregnancy, by hormones) or externally (eg,
trauma, surgery). These lesions carry a significant risk of a
recurrence, especially after suboptimal treatment. EVMs
can be difficult to assess by observation alone. This type of
lesion more commonly involves deep soft-tissue structures
such as muscle and bone.3,4 Although the symptoms are
related to the size and location of the lesion, what is
impressive is the pain that results from this type of lesion.
Even if the lesion is small and difficult to find, the patient
can present with nearly constant pain. If these lesions are
extensive, involving an entire extremity, the resulting pain
can be remarkably disabling.
The traditional conservative approach is recommended
for almost all EVM lesions. Asymptomatic patients should
undergo observation only. A tailored compression garment
(if anatomically possible) is the first-line treatment for
symptomatic lesions. Resection is not indicated owing to a
large amount of blood loss, and incomplete resection car-
ries the risk of recurrence and usually poor cosmetic re-
sults.5,8 Lately, absolute ethanol has been accepted as a new
scleroagent and is associated with a substantial reduction of
recurrence. Absolute ethanol induces denaturation of tissue
protein, resulting in the precipitation of protoplasm and
subsequent permanent obliteration of the vessel lumen. It
is the only clinically tested scleroagent known to stop the
regeneration of endothelial cells, with the prospect of cure
in selected cases. However, it is extremely dangerous be-
cause of various toxicity-related complications. Thus, the
issues of the safety and efficacy of absolute ethanol for the
treatment of VMs remain unclear.7,9,13
In the last 20 years, there have been many attempts at
laser treatment of VMs. Laser sources have included argon,
neodymium:yttrium-aluminum-garnet (Nd:YAG; 1064
nm), potassium titanyl phosphate frequency-doubled Nd:
YAG (532 nm), copper vapor, flash lamp pumped pulsed
dye, and broad-spectrum intense pulsed light sources.
However, laser use was often limited by the poor absorp-
tion of light in deep blood vessels or the high prevalence of
side effects.14-16
Greater successwas recently reported for the diode laser in
the treatment of superficial venous insufficiency.10,11 The
diode laser was developed to have a more selective action
against blood vessels than previous lasers. The diode laser
operates at wavelengths of 940 or 810 nm, which is selec-
tive for the tertiary hemoglobin peak, and has a depth of
penetration in blood of just 0.3 mm, making it more
suitable for venous treatment.17,18
Two mechanisms of action of endovenous thermal
ablation have been suggested. The first is indirect heating
and damage to the vein wall by intravascular generation of
steam bubbles, resulting in thrombotic occlusion of the
vein. The second involves direct heating and damage to
the vein wall, resulting in shrinkage and closure of the
vein.19,20 Laser-induced necrosis of blood vessels typically Wnvolves the absorption of light by hemoglobin and the
iffusion of heat through blood, vein walls, and surround-
ng tissue, resulting in fibrotic occlusion of the vein.21 Laser
reatment affects only the channels in which microbubbles
re formed and distributed; it does not alter the biologic
bnormality of the remaining channels and affected tis-
ue.22
We treated patients with EVMs with a diode laser using
n endovenous technique. We monitored these patients to
valuate if the laser treatment caused improvement or dis-
ppearance of symptoms, which was our treatment goal. In
ur small series, we achieved partial or complete pain relief
n all patients (100%). With respect to complaints related to
welling and cosmetic effect, the clinical success was 70%
nd 67%, respectively. Better results were obtained with the
ocalized type of VM, in which palliation was achieved after
nly one treatment. Patients with diffuse lesions had to
ave repeat sessions, with relief of symptoms in residual
esions. VMs are dynamic lesions, with pain usually experi-
nced if the abnormal veins are in a state of distension
ecause of effort or position. It is probable that the pain is
aused by the stretching of nerve endings within the vein
all or in adjacent tissues.7,13
The complications that arose in our patient group from
iode laser treatment were potentially avoidable or amend-
ble, and most were self-limiting. No major complications
uch as deep vein thrombosis, pulmonary embolism, or
ematoma developed, and all of the minor complications
esolved without sequelae. Theoretically, an 810-nm diode
aser beam will penetrate about 0.3 mm into tissue. Diode
aser treatment offers many potential benefits over surgical
xcision and cutaneously applied laser therapy:
. It is minimally invasive and requires only small puncture
sites in the skin.
. It can treat large lesions with little intraoperative and
postoperative bleeding.
. The surgeon can tailor the amount of laser to treat VMs
of varying severity.
. The end point of treatment is easy to determine.
. Total operative time is dramatically reduced.
. Postoperative care is simple, with little need for wound
care.
ONCLUSIONS
Treatment of congenital EVMs with endovenous laser
blation under US guidance achieved palliation in most
ymptomatic patients; it was safe, with minimal morbidity
uring short-term follow-up. Future prospective studies
nd long-term follow-up will be useful to further define the
ole of this procedure in the treatment of congenital EVMs.
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The article by Dr Xin-Wu Lu and collaborators brings further
and important information on the therapeutic benefits of laser
energy in the management of venous malformations, which con-
stitute the most common form of congenital vascular anomalies.
During the last 2 decades, different forms of laser have been
used to treat superficial skin blemishes and relatively accessible
anomalies of different organs.
Traditionally, the management of deeply seated symptomatic
venous malformations either localized or infiltrating, has been by (1)
surgery, (2) sclerotherapy in any of its physical forms (liquid or foam),
and (3) embolization of different materials (coils, glue). Particularly
successful even though controversial because of its severe side effects
and the need of expertise in its application, has been the use of
ethanol, a potent scleroagent of recognized efficacy.
I disagree with the authors that surgery should be avoided
because “resection may be hazardous, leading to major loss of
blood and incomplete resection and recurrence.” Surgery can be
safely and cleanly performed in a bloodless field using controlled
tourniquet ischemia, as I and others have published. This is appli-
cable to localized and infiltrating types of deeply seated lesions.ood news. The relatively safe and effective use of endovenous laser
s the authors described, may replace the controversial use of
thanol sclerotherapy in some deeply seated venous malformations
lose to vital structures such as nerves, arteries, or large veins where
he “leak” of ethanol into nontargeted structures could lead to
evere sequelae. Furthermore, endovenous laser therapy may find
ts place as a preoperative step in shrinking bulky venous malfor-
ations facilitating its subsequent surgical excision.
The authors’ 96% of good-to-excellent results with minimal
omplications are encouraging. These results may entice others to
xpand the use of diode laser or other forms of laser to the
ndovascular treatment of the large venous plexuses in malforma-
ions such as Klippel-Trenaunay syndrome (KTS). A few publica-
ions have described the ultrasound-guided endovascular use of
he neodymium:yttrium-aluminum-garnet 1064 laser in the treat-
ent of the large veins accompanying KTS, but prospective studies
ith larger numbers of patients and longer follow-up are necessary.
ood imaging techniques, better and thinner laser probes, and
reation of multidisciplinary teams dedicated to congenital anom-
lies may be the best present that these unfortunate patients will
ver get.
